Skip to content

Merck & Co. MRK Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Pfizer logo
PfizerPFE
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Cytokinetics logo
CytokineticsCYTK
Phibro Animal Health logo
Phibro Animal HealthPAHC
United Therapeutics logo
United TherapeuticsUTHR

Other financials

Income statement

See full
Revenue$16.3B+4.9%
Gross profit$12.1B-0.2%
Net income-$4.2B-183%
EPS (diluted)-$1.72-186%

Balance sheet

See full
Cash & equivalents$5.4B-38.2%
Total debt$49.1B+35.8%
Total equity$45.9B-5.1%
Total assets$128.69B+11.8%

Cash flow

See full
Operating cash flow$3.9B+56.7%
CapEx$991.0M-25.4%
Free cash flow$2.9B+150%

Valuation

See full
Market cap$323.72B+53.4%
Enterprise value$367.42B+53.2%
P/E36.2×+23.4×
P/S4.9×+1.6×

Profitability

See full
Gross margin73.9%-2.5pp
Net margin13.6%-13.7pp
FCF margin21.5%-5.2pp

Returns & leverage

See full
Return on equity19%-20.3pp
Debt / equity1.1×+0.3×
Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Merck & Co.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merck & Co.'s deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Merck & Co.'s deferred tax assets and other non-current assets?
Merck & Co. (MRK) reported deferred tax assets and other non-current assets of $19.81B in Q1 2026.
How has Merck & Co.'s deferred tax assets and other non-current assets changed year-over-year?
Merck & Co.'s deferred tax assets and other non-current assets increased by 18.1% year-over-year, from $16.77B to $19.81B.
What is the long-term trend for Merck & Co.'s deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Merck & Co.'s deferred tax assets and other non-current assets has grown at a 10.7% compound annual growth rate (CAGR), from $743M to $1.24B.